ERBB2 and adenocarcinoma: In addition, in G/GEJ adenocarcinoma with low HER2 expression (HER2 IHC 1+ and IHC 2+/FISH-), ADCs (e.g., Disitamab vedotin, DS-8201) use cleavable connexons that can release payloads before internalization, some of which are hydrophobic or nonpolar payloads that can easily cross cell membranes.